John Rector
|
When First DataBank agreed to settle a lawsuit last month and pledged to stop publishing AWP (average wholesale price) data
in two years, it sent ripples through the pharmacy industry. AWP has long been a key measure for determining pharmacy payments,
and there is no easy answer for how to replace it. As John Rector, senior VP and general counsel at the National Community
Pharmacists Association, cautioned, "This is the very beginning of what will probably be a very lengthy process."
The case stems from a complaint filed in the U.S. District Court for the District of Massachusetts last year by the Prescription
Access Litigation (PAL) Project against First DataBank and McKesson. PAL, a coalition that includes union-backed health plans,
alleged that First DataBank and McKesson carried out an illegal scheme to raise the price of prescription drugs by inflating
AWP. The lawsuit claimed that beginning in 2002, McKesson and First DataBank began arbitrarily raising the WAC (wholesale
acquisition cost)-to-AWP spread to 25% for more than 400 brand-name drugs. According to the complaint, those drugs previously
had only a 20% WAC-to-AWP spread.
Stephen Schondelmeyer
|
Although the settlement has not been approved by the judge yet, most experts consider it the end of the use of AWP. "The settlement
is the final death knell for AWP," commented Stephen Schondelmeyer, Pharm.D., Ph.D., director of the PRIME Institute at the
University of Minnesota College of Pharmacy. "AWP has lost its credibility—it's considered subject to manipulation."
In the settlement, First DataBank admitted no wrongdoing but pledged to take a number of steps over the next two years. Sixty
days after the agreement is finalized, First DataBank will adjust its reporting of Blue Book AWP for certain prescription
drugs by reducing the markup factor to 20%. In addition, First DataBank will discontinue publishing the Blue Book AWP data
altogether within two years. The company has also pledged to help find a new benchmark. In a written statement, First DataBank sought to assure the industry: "We will institute these changes in a responsible fashion,
in an effort to minimize the effect on our customers and the beneficiaries of reimbursement. However, as a responsible publisher
that is dedicated to reporting relevant and reliable drug information, we do not believe that the Blue Book AWP field can
be published by us or any other compendia as a sustainable reimbursement benchmark."
Some experts cautioned that lesser-known parts of the settlement may also have a significant impact on the industry. "From
our sector's point of view, there are some very problematic aspects of the settlement," said Rector. As part of the settlement,
First DataBank will make available all the documents that it has relevant to the AWP issue, which could lead to new litigation.
First DataBank is "held harmless and nobody else is. Who knows what data they have?" Rector asked.
Some of that uncertainty will undoubtedly continue. Although First DataBank has agreed to the settlement, the case continues
on with McKesson as the sole defendant. In a statement, the company pledged that "the claims against McKesson have no merit,
and we will defend ourselves vigorously. McKesson does not set AWP. First DataBank sets AWP.... If First DataBank decided
to survey McKesson only, it did so without telling McKesson." Alex Sugerman-Brozan, director of PAL, has pledged to pursue
the McKesson litigation aggressively.
The impact of the settlement remains to be seen. As CVS noted in a written statement meant to calm investor concern: "In the
event AWPs were suddenly reduced in a material way for particular products, obviously we would renegotiate the discount or
dispensing fee. Virtually all of our commercial agreements are 'at-will' agreements, which can be renegotiated freely." The
statement does not specify what will replace AWP in the contracts.
Drug Topics archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.